Basic Information
Optimvia is a biopharmaceutical company specializing in engineered enzymes and their cofactors for the synthesis of complex therapeutic molecules, utilizing its ADEPT™ platform to design enzymes, enzyme systems, and cofactors. The first breakthrough product of the ADEPT platform is biosynthetic heparin. The company creates new enzymes and cofactors to recapitulate the natural synthesis of heparin. Biosynthetic heparin is the first commercial candidate drug developed by Optimvia using its ADEPT™ platform.